Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator

Current Pharmaceutical Design

Volumn 16, Issue 10, 2010, Pages 1224-1234

  Sikiric, Predrag ^a   Seiwerth, Sven ^a   Brcic, Luka ^a   Sever, Marko ^a   Klicek, Robert ^a   Radic, Bozo ^a   Drmic, Domagoj ^a   Ilic, Spomenko ^a   Kolenc, Danijela ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Adaptive cytoprotection; Cytoprotection; Stable gastric pentadecapeptide BPC 157

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATROPINE; BLOOD CLOTTING FACTOR 8; CD34 ANTIGEN; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEPRAZOLE; RANITIDINE; VASCULOTROPIN;

ADAPTATION; ADJUVANT ARTHRITIS; ANGIOGENESIS; CELL PROTECTION; COLON FISTULA; DRUG STABILITY; ENTERITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA INJURY; STOMACH PROTECTION; WOUND HEALING;

ANIMALS; ANTI-ULCER AGENTS; CYTOPROTECTION; GASTRIC ACID; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; PEPTIDE FRAGMENTS; PROTEINS; RATS; STOMACH ULCER; WOUND HEALING;

EID: 77950882022     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790945977     Document Type: Review

References (83)

1. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15aminoacid peptide BPC fragment, on gastric and duodenal lesioninduced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopaminepromoters and gut peptides. Life Sci 1994; 54: PL63-8.
2. Skorjanec S, Dolovski Z, Kocman I, Brcic L, Blagaic Boban A, Batelja L, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. Dig Dis Sci 2009; 54: 46-56.
3. Klicek R, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL 14736, Pliva), is effective in the healing of colocutaneous fistulas in rats: the role of NO-system. J Pharm Sci 2008; 108: 7-17.
4. Sever M, Klicek R, Radic B, Brcic L, Zoricic I, Drmic D, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci 2009; 54: 2070-2083.
5. Prkacin I, Aralica G, Perovic D, Separovic J, Gjurasin M, Lovric-Bencic M, et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris 2001; 95: 295-301. (Pubitemid 33020253)
6. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33. (Pubitemid 27346600)
7. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 1997; 91: 113-122. (Pubitemid 27467014)
8. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagić V, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci 1996; 41: 1604-14.
9. Sikiric P, Seiwerth S, Aralica G, Perovic D, Staresinic M, Anic T, et al. Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. J Physiol Paris 2001; 95: 283-288.
10. Sikiric P, Seiwerth S, Grabarevic Z, Balen I, Aralica G, Gjurasin M, et al. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol Paris 2001; 95: 261-270. (Pubitemid 33020248)
11. Veljaca M, Pavic Sladoljev D, Mildner B, Brajsa K, Bubenik M, Stipanicic S, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003; 51 (Suppl III): A309.
12. Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J, Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128: A584.
13. Sikiric P, Seiwerth S, Mise S, Staresinic M, Bedekovic V, Zarkovic N, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-334. (Pubitemid 36627674)
14. Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns 2001; 27: 817-27.
15. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003; 21: 976-983.
16. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006; 24: 982-989.
17. Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-725.
18. Tkalcevic VI, Cuzic S, Brajsa K, Mildner B, Bokulic A, Situm K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570: 212-221.
19. Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-1117.
20. Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha and BPC-15 in human gastric juice. Gastroenterology 1995; 108: A761.
21. Robert A. Cytoptotection by prostaglandins. Gastroenterology 1979; 77: 761-767.
22. Robert A, Nezamis JE, Lancaster C, Davis JP, Field SO, Hanchar AJ. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol 1983; 245: G113-21.
23. Robert A. Cytoprotection and adaptive cytoprotection. In: Nelis GF, Boeve J, Misiewicz JJ, Eds. Peptic ulcer disease: Basic and clinical aspects. Dordrecht: Martinus Nijhoff Publishers 1985; pp. 297-316.
24. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol 2004; 499: 285-290.
25. Prkacin I, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris 2001; 95: 315-324. (Pubitemid 33020256)
26. Boban-Blagaic A, Blagaic V, Romic Z, Jelovac N, Dodig G, Rucman R, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Med Sci Monit 2006; 12(1): BR36-45.
27. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 1997; 91: 113-122. (Pubitemid 27467014)
28. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvić I, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993; 87: 313-327. (Pubitemid 23343538)
29. Sikiric P. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology 1999; 7: 1-14. (Pubitemid 29274787)
30. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006; 14: 214-221.
31. Wood JD.The first nobel prize for integrated systems physiology: Ivan Petrovich Pavlov, 1904. Physiology (Bethesda) 2004; 19: 326-330.
32. Morón F, Pena C, Cuesta E, Mózsik G, Jávor T. Comparative study of the cytoprotective effects of anticholinergic agents on the gastric mucosal lesions produced by intragastric administration of 0.6 M HCl in rats. Acta Physiol Hung 1984; 64: 247-252.
33. Clissold SP, Campoli-Richards DM. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.
34. Szabo S. Experimental basis for a role for sulfhydryls and dopamine in ulcerogenesis: a primer for cytoprotection - organoprotection. Klin Wochenschr 1986; 64 (Suppl 7): 116-122. (Pubitemid 17028609)
35. Szabo S, Usadel KH. Cytoprotection - organoprotection by somatostatin: gastric and hepatic lesions. Experientia 1982; 38: 254-256. (Pubitemid 12107042)
36. Taché Y, Yoneda M, Kato K, Király A, Sütö G, Kaneko H. Intracisternal thyrotropin-releasing hormone-induced vagally mediated gastric protection against ethanol lesions: central and peripheral mechanisms. J Gastroenterol Hepatol 1994; 9 (Suppl 1): S29-35.
37. Sikiric P, Rotkvic I, Mise S, Krizanac S, Gjuris V, Jukic J, et al. The influence of dopamine agonists and antagonists on indomethacin lesions in stomach and small intestine in rats. Eur J Pharmacol 1988; 158: 61-67. (Pubitemid 19008803)
38. Szabo S. Critical and timely review of the concept of gastric cytoprotection. Acta Physiol Hung 1989; 73: 115-127.
39. Sikiric P, Mikus D, Seiwerth S, Grabarevic Z, Rucman R, Petek M, et al. Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. Dig Dis Sci 1997; 42: 1029-1037. (Pubitemid 27239796)
40. Bedekovic V, Mise S, Anic T, Staresinic M, Gjurasin M, Kopljar M, et al. Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. Eur J Pharmacol 2003; 477: 73-80. (Pubitemid 38366088)
41. Szabo S, Neumeyer JL. Dopamine agonists and antagonists in duodenal ulcer disease. In: Kaiser C, Kebabian W, Eds. Symposium Series. Washington: ACS American Chemical Society Publications 1983; 224: 175-196.
42. Seto Y, Kobori O. Role of reflux oesophagitis and acid in the development of columnar epithelium in the rat oesophagus. Br J Surg 1993; 80: 467-470. (Pubitemid 23116086)
43. Sikiric P, Jadrijevic S, Seiwerth S, Sosa T, Deskovic S, Perovic D, et al. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J Physiol Paris 1999; 93: 467-477. (Pubitemid 30038580)
44. Petrovic I, Dobric I, Drvis P, Shejbal D, Brcic L, Blagaic AB, et al. An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci 2006; 102: 269-277. (Pubitemid 44790688)
45. Dobric I, Drvis P, Petrovic I, Shejbal D, Brcic L, Blagaic AB, et al. Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157. J Pharmacol Sci 2007; 104: 7-18. (Pubitemid 46790311)
46. Sikiric P, Seiwerth S, Deskovic S, Grabarevic Z, Marovic A, Rucman R, et al. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Eur J Pharmacol 1999; 364: 23-31. (Pubitemid 29015783)
47. Mise S, Tonkic A, Pesutic V, Tonkic M, Mise S, Capkun V, et al. The presentation and organization of adaptive cytoprotection in the rat stomach, duodenum, and colon. Dedicated to André Robert the founder of the concept of cytoprotection and adaptive cytoprotection. Med Sci Monit 2006; 12: BR146-53.
48. Robert A, Lancaster C, Olafsson AS. Gastric adaptation to the ulcerogenic effect of aspirin. Exp Clin Gastroenterol 1991; 1: 73-81.
49. Lazarus R, Folkman S, Eds. Stress appraisal and coping. New York: Springer Publishing Company 1984.
50. Pawlik WW, Sikiric P, Brzozowski T, Seiwerth S, Drozdowicz D, Pajdo R, et al. Acceleration of ulcer healing by pentadecapeptide BPC 157 in rats. Involvement of endogenous prostaglandins and gastric secretion. Gastroenterology 2004; 126: 541.
51. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci 1996; 41(7): 1518-1526. (Pubitemid 26245938)
52. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 1993; 53(18): PL291-6.
53. Ilic S, Brcic I, Mester M, Filipovic M, Sever M, Klicek R, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 2010; 61(Suppl 7): in press.
54. Tudor M, Jandric I, Marovic A, Gjurasin M, Perovic D, Radic B, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32.
55. Hrelec M, Klicek R, Brcic L, Brcic I, Cvjetko S, Seiwerth S, et al. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. J Physiol Pharmacol 2010; 61 (Suppl 7): in press.
56. Szabo S, Vincze A. Growth factors in ulcer healing: lessons from recent studies. J Physiol (Paris) 2000; 94: 77-81. (Pubitemid 30202857)
57. Urist MR. The first three decades of bone morphogenetic protein. Osteologie 1996; 4: 207-233.
58. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Duel TF. Accelarated healing of incisional wounds in rats induced by transforming growth factor-b. Science 1987; 237: 1333-1336. (Pubitemid 17125439)
59. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today 2007; 37: 768-777. (Pubitemid 47312514)
60. Kalogjera L, Ries M, Baudoin T, Ferencic Z, Trotic R, Pegan B. Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. Eur Arch Otorhinolaryngol 1997; 254(Suppl1): S9-11. (Pubitemid 27110347)
61. Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept 2010; [Epub ahead of print].
62. Lamarque D, Whittle BJ. Increase in gastric intramucosal hydrogen ion concentration following endotoxin challenge in the rat and the actions of nitric oxide synthase inhibitors. Clin Exp Pharmacol Physiol 2001; 28: 164-168. (Pubitemid 32193658)
63. Bayir Y, Odabasoglu F, Cakir A, Aslan A, Suleyman H, Halici M, et al. The inhibition of gastric mucosal lesion, oxidative stress and neutrophil- infiltration in rats by the lichen constituent diffractaic acid. Phytomedicine 2006; 13: 584-590. (Pubitemid 44224043)
64. Murakami I, Satoh H, Asano S, Maeda R. Role of capsaicin-sensitive sensory neurons and nitric oxide in the protectiveeffect of lansoprazole, a proton pump inhibitor, on the gastricmucosa in rats. Jpn J Pharmacol 1996; 72: 137-147. (Pubitemid 26390724)
65. Grabarevic Z, Tisljar M, Artukovic B, Bratulic M, Dzaja P, Seiwerth S, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol (Paris) 1997; 91: 139-149. (Pubitemid 27467018)
66. Turkovic B, Sikiric P, Seiwerth S, Mise S, Anic T, Petek M, et al. Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD-116, PL14736, Pliva) induces nitric oxide synthesis. Gastroenterology 2004; 126: 287.
67. Lovric-Bencic M, Sikiric P, Separovic J, Seiwerth S, Rogic D, Kusec V, et al. Doxorubicine congestive heart failureincreased bigendothelin 1 plasma concentration. Reversal by amlodipine, losartan and gastric pentadecapeptide BPC 157 in rat and mouse. J Pharmacol Sci 2004; 95: 19-26.
68. Balenovic D, Bencic ML, Udovicic M, Simonji K, Hanzevacki JS, Barisic I, et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept 2009; 156: 83-89.
69. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2 blockersand sucralfate on new vessels and new granulation tissue formation. J Physiol (Paris) 1999; 93: 479-485. (Pubitemid 30038581)
70. Mózsik G, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157(PLD116, PL14736, Pliva) infl uences ATP energy system and antagonizes 0.6 M HCl- and 96 % ethanl-gastric lesion in rat. Digestion 2005; 73 (Suppl. 2): 41.
71. Whittle BJR, Boughton-Smith NK, Moncada S. Biosynthesis and role of the endothelium-derived vasodilator, nitric oxide in gastric mucosa. Ann NY Acad Sci 1992; 664: 126-139.
72. Frank S, Madlener M, Pfeilschifter J, Werner S. Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin- cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. J Invest Dermatol 1998; 111: 1058-1064.
73. Cerovecki T, Bojanic I, Brcic L, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthopaed Res 2010; (in press).
74. Brcic L, Brcic I, Staresinic M, Noviscak T, Sikiric P, Seiwerth S. Modulatory effect of stable gastric pentadecapeptide on angiogenesis in muscle and tendon healig. J Physiol Pharmacol 2010; 61: (Suppl 7), in press.
75. Rao KS, Patil PA, Malur PR. Promotion of cutaneous wound healing by famotidine in Wistar rats. Indian J Med Res 2007; 125: 149-154.
76. Rantfors J, Cassuto J. Role of histamine receptors in the regulation of edema and circulation postburn. Burns 2003; 29: 769-777.
77. Numata Y, Terui T, Okuyama R, Hirasawa N, Sugiura Y, Miyoshi I, et al. The accelerating effect of histamine on the cutaneous wound-healing process through the action of basic fibroblast growth factor. J Invest Dermatol 2006; 126: 1403-1409.
78. Misiewicz JJ. Future trends in the management of peptic ulcer disease. Scand J Gastroenterol Suppl 1985; 146: 175-184.
79. Karadi O, Nagy Z, Bodis B, Mozsik G. Atropine-induced gastrointestinal cytoprotection dependences to the intact of vagal nerve against indomethacin-induced gastrointestinal mucosal and microvascular damage in rats. J Physiol (Paris) 2001; 95: 29-33.
80. Klicek R, Sever M, Ilic S, Dobric I, Petrovic I, Filipovic M, et al. Peptide in clinical trials for inflammatory bowel disease (PL14736, Pliva), gastric pentadecapeptide BPC 157 is effective int he healing oft he chronic colocutaneous fistula sin rats. J Physiol Pharmacol 2009; 60 (Suppl 2): 45.
81. Evangelista S. Role of calcitonin gene-related Peptide in gastric mucosal defence and healing. Curr Pharm Des 2009; 15(30): 3571-3576.
82. Nemeth E, Bernath J. Biological activities of yarrow species (Achillea spp.). Curr Pharm Des 2008; 14(29): 3151-3167.
83. Nishihira J, Mitsuyama K. Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease. Curr Pharm Des 2009; 15(18): 2104-2109.